While loss of Kif18A function seems to be tolerated by euploid cells, it is crucial for the survival of certain aneuploid cancers, revealing its strong potential as an antitumor therapeutic target (Gomes et al., 2022; Sepaniac et al., 2021; Quinton et al., 2021; Cohen-Sharir et al., 2021; Marquis et al., 2021; Payton et al., 2024; Gliech et al., 2024). This evidence concerns the gene KIF18A and cancer.